|
|
|
| home > ebr > winter 2022 > bioelectronic assay identifies potential covid-19 therapeutic targets |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
COVID-19 is continuing to spread around the world, with roughly 300 million confirmed cases and more than five million deaths (1). Health officials cite numerous causes for this ongoing threat, including wavering vaccine supply and demand, the emergence of new variants, and a lack of effective therapeutics for the disease. Although mitigation efforts are ongoing, epidemiologists predict the likeliest long-term outcome is that the SARS-CoV-2 virus will become endemic in large regions around the world, constantly circulating among the human population (2). To help reduce the impact of COVID-19 on global health, any long-term management strategy must include the creation of safe and effective antiviral drugs.
Identifying a COVID-19 Treatment Strategy
Historically, scientists have found it difficult to develop antiviral drugs for several reasons. Firstly, viruses only contain the genetic material and proteins they need to travel through cell membranes and hijack a cell’s replication machinery. As a result, they do not possess many ideal drug targets. Also, because viruses rely so much on cells to operate, it is challenging to develop a drug that neutralises the virus without interfering with normal physiological processes.
Furthermore, viruses mutate frequently, making it hard to identify a stable target that will be useful over a long period of time. In fact, although SARS-CoV-2 was only discovered two years ago, scientists have already identified highly contagious variants that may result in more severe and/or transmissible disease and threaten the efficacy of today’s vaccines. Consequently, ideal antiviral drugs must target a portion of the virus or a related process that does not change.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Shionogi, Active Citizenship Network and Meps Advocate for Urgent Policy Implementation in Eu Member States at Eu Parliament Event to Address the Growing Threat of Antimicrobial Resistance
OSAKA, Japan and AMSTERDAM, NL, 28 November 2022 – Shionogi &
Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter
"Shionogi"), held an event at the EU Parliament last week in the run-up
to World Antimicrobial Awareness Week, joining forces with MEPs, Active
Citizenship Network and MEPs Interest Group on "European Patients'
Rights & Cross-Border Healthcare" to discuss initiatives to tackle
AMR. The event reinforced the need for urgent attention and
collaboration from pharmaceutical companies, policy stakeholders and
governments to bring about policy change and innovation to address this
growing issue.
More info >> |
|
 |
White Papers |
 |
|
Advanced BioDesign Outlines Solutions
Advanced BioDesign
Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >> |
|
|
